Global Oncology Academy

How Testing for Acquired vs. Intrinsic Mutations in HR+/HER2- Metastatic Breast Cancer Differs

ReachMD Healthcare Image
RestartResume

Explore the key differences in testing for acquired mutations and intrinsic mutations in patients with HR+/HER2- metastatic breast cancer.

Take Post-Survey

If you’ve already completed the activity.

  • Overview

    While intrinsic mutations, like PIK3CA, are present at the outset and can be identified upfront in patients with HR+/HER2- metastatic breast cancer, acquired mutations, like ESR1, cannot be detected on baseline tumor profiling. That’s why longitudinal monitoring with liquid biopsies over the course of treatment is required. Learn more about these key differences in testing for acquired versus intrinsic mutations with Dr. Megan Kruse, a breast medical oncologist at the Cleveland Clinic.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free